Vital Farms Faces Twin Storms: Legal Investigation and Institutional Flight

The egg producer Vital Farms is weathering a punishing stretch on multiple fronts. A US law firm has launched an inquiry into possible misconduct by company executives, while institutional investors are bailing out in droves. The shares tumbled 8.52% on Friday to EUR 8.87, pushing the year-to-date decline to roughly 65%.

Bronstein, Gewirtz & Grossman is probing whether Vital Farms and certain managers violated securities laws. The investigation zeroes in on investors who bought the stock before May 8, 2025. No formal findings have been announced, but the mere spectre of legal action has compounded the selling pressure.

The timing is especially painful: the company’s first-quarter 2026 results, released in early May, showed revenue climbing 15.4% to $187.2 million, yet the bottom line swung to a net loss of $1.5 million from a profit of $16.9 million a year earlier. The sharp reversal rattled confidence across the shareholder base.

Professional money managers have already voted with their feet. The Wasatch Small Cap Growth Strategy slashed its stake in the first quarter of 2026, citing intense competition and shrinking market share. The Osterweis Opportunity Fund went further, liquidating its entire position after losing faith in management’s ability to deliver on long-term profitability. The total number of hedge funds holding the stock has dropped from 36 to 33.

Should investors sell immediately? Or is it worth buying Vital Farms?

In response to the deteriorating operating environment, Vital Farms is pulling out of the butter business by the end of 2026 and refocusing on its core free-range egg operations. Chief Financial Officer Thilo Wrede described the decision as a “prudent reaction to the current pricing environment,” aimed at preserving margins through operational discipline. The company now forecasts full-year revenue of $775 million to $800 million.

At last week’s annual general meeting, shareholders re-elected two directors and reappointed KPMG as auditor – a routine session that offered little reprieve for the stock. The shares closed on Friday at EUR 8.87, some 73% below the record high of EUR 33.60 set in November 2025. The relative strength index sits at 46.9, a technically neutral reading that offers faint comfort given the stock’s near-60% volatility and its proximity to the year’s low of EUR 6.80 touched on May 7, 2026.

Investors are now watching for the next batch of market-share data. A stabilisation in the competitive landscape would be the first step toward breaking the downward spiral – but with legal uncertainty hanging overhead, any recovery remains contingent on a clean bill of health.